newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class,